Latest news
25 items- PRRxSight, Inc. Appoints Raymond W. Cohen to Its Board of DirectorsALISO VIEJO, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the appointment of Raymond W. Cohen to its Board of Directors. "We are thrilled to welcome Raymond W. Cohen to the RxSight Board of Directors," said J. Andy Corley, Chairman of the Board at RxSight. "Ray's extensive track record in leading and scaling medical technology companies will be invaluable as we advance our strategy and enter the next phase of growth. His insights and guidance will help us expand the reach of the RxSight® Light Adjustable Lens system,
- SECSEC Form 15-12G filed by Axonics Inc.15-12G - Axonics, Inc. (0001603756) (Filer)
- SECSEC Form EFFECT filed by Axonics Inc.EFFECT - Axonics, Inc. (0001603756) (Filer)
- SECSEC Form 25-NSE filed by Axonics Inc.25-NSE - Axonics, Inc. (0001603756) (Subject)
- INSIDERDirector Kiernan Jane E returned $1,410,131 worth of shares to the company (19,861 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDEREVP, Chief Mktg/Strtgy Officer Woock John returned $5,495,613 worth of shares to the company (77,403 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERDirector Snyderman Nancy Lynn Md returned $1,061,024 worth of shares to the company (14,944 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERChief Operating Officer Sama Rinda returned $5,996,802 worth of shares to the company (84,462 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERChief Medical Officer Noblett Karen returned $2,444,388 worth of shares to the company (34,428 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERDirector Lopez Esteban returned $468,600 worth of shares to the company (6,600 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERDirector Mcnamara Robert returned $1,055,131 worth of shares to the company (14,861 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERChief Commercial Officer Ford Alfred J Jr returned $3,084,950 worth of shares to the company (43,450 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERChief Financial Officer Keese Kari Leigh returned $2,865,702 worth of shares to the company (40,362 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERDirector Demski David M returned $677,482 worth of shares to the company (9,542 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERChief Executive Officer Cohen Raymond W returned $20,783,901 worth of shares to the company (292,731 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERDirector Carrel Michael H returned $1,268,131 worth of shares to the company (17,861 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- SECSEC Form POS AM filed by Axonics Inc.POS AM - Axonics, Inc. (0001603756) (Filer)
- SECSEC Form S-8 POS filed by Axonics Inc.S-8 POS - Axonics, Inc. (0001603756) (Filer)
- SECSEC Form S-8 POS filed by Axonics Inc.S-8 POS - Axonics, Inc. (0001603756) (Filer)
- SECAxonics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Axonics, Inc. (0001603756) (Filer)
- PRBoston Scientific Closes Acquisition of Axonics, Inc.MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (NASDAQ:AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. "Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence," said Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. "By closing this acquisiti
- INSIDERDirector Snyderman Nancy Lynn Md gifted 5,000 shares, decreasing direct ownership by 25% to 14,944 units (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- SECSEC Form 10-Q filed by Axonics Inc.10-Q - Axonics, Inc. (0001603756) (Filer)
- SECAxonics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Axonics, Inc. (0001603756) (Filer)
- PRAxonics Reports Third Quarter 2024 Financial ResultsAxonics, Inc. (NASDAQ:AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2024. "Axonics continued to execute at a high level in the third quarter, generating revenue growth of 25% year over year," said Raymond W. Cohen, chief executive officer. "Revenue growth for both sacral neuromodulation and Bulkamid® was driven by higher utilization at existing customers and the onboarding of new accounts." Mr. Cohen continued, "Our commitment to innovation, quality, direct-to-consumer advertising and providing str
AXNX FAQ
7 questionsWhat does Axonics Inc. do?
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers...Where does AXNX stock trade?
Axonics Inc. (AXNX) is listed on NASDAQ.What sector and industry is AXNX in?
Axonics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Axonics Inc. go public?
Axonics Inc. (AXNX) completed its IPO in 2018.What are analysts saying about AXNX?
Axonics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2024-01-09.What companies are similar to AXNX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare AXNX side-by-side with any of them on Quantisnow.How can I track AXNX on Quantisnow?
Quantisnow aggregates Axonics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AXNX to receive live email and push alerts on every new disclosure.